Tectonic Therapeutic

Historical price data

Tectonic Therapeutic is a clinical-stage biotech focused on unlocking the vast therapeutic potential of G-Protein Coupled Receptors (GPCRs) through its proprietary GEODe™ platform for biologic drug discovery. Founded on foundational research from Harvard Medical School and led by a deeply experienced pharmaceutical R&D team, the company's mission is to develop transformative medicines for cardiopulmonary and fibrotic diseases. Its strategy centers on advancing its lead Fc-relaxin fusion program, TX000045, through clinical proof-of-concept while leveraging its platform to build a pipeline of novel GPCR-targeted biologics.

The GEODe™ (GPCR Effector Optimization and Discovery) platform is a proprietary technology designed to discover and develop biologic therapeutics, such as antibodies and engineered proteins, that selectively modulate the activity of G-Protein Coupled Receptors (GPCRs) by targeting their complex signaling conformations.

In HFpEF/PH, Tectonic competes with large pharma and other biotechs developing small molecules and biologics. Its differentiation lies in its relaxin-based biologic approach. At the platform level, it competes with other companies targeting GPCRs with novel modalities, where its deep structural biology expertise is a key differentiator.